Mexican Drugmaker Cited for Multiple Violations

Drug Industry Daily
A A
The FDA handed Mexican drugmaker Degasa a Form 483 with 12 observations listing the many noncompliance issues found during an inspection of its Jiutepec, Morelos facility, including faulty recordkeeping, inadequate testing and poor quality controls.

To View This Article:

Login

Subscribe To Drug Industry Daily